CH518927A - Glucosides cytostatic activity - Google Patents

Glucosides cytostatic activity

Info

Publication number
CH518927A
CH518927A CH1489370A CH1489370A CH518927A CH 518927 A CH518927 A CH 518927A CH 1489370 A CH1489370 A CH 1489370A CH 1489370 A CH1489370 A CH 1489370A CH 518927 A CH518927 A CH 518927A
Authority
CH
Switzerland
Prior art keywords
general formula
formyl
glucopyranose
ethylidene
acetyl
Prior art date
Application number
CH1489370A
Other languages
German (de)
Inventor
Kuhn Max
Camilla Dr Keller-Juslen
Renz Jany
Wartburg Albert Von
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Priority to CH1489370A priority Critical patent/CH518927A/en
Publication of CH518927A publication Critical patent/CH518927A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/54Preparation of carboxylic acid anhydrides
    • C07C51/56Preparation of carboxylic acid anhydrides from organic acids, their salts, their esters or their halides, e.g. by carboxylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Saccharide Compounds (AREA)

Abstract

Glucosides of general formula (I): R1=alkyl (C1-5). (I) have in vitro a strong cytostatic activity to mastocytoma cells and fibroblast cultures. They also have high activity against experimental tumours esp. mouse leukemia L-210. They may be used therapeutically against pathological processes connected with cell multiplication such as malignant neoplasms. R2=formyl or acetyl (II) is reacted with (III) in the presence of borontrifluoride etherate at -15 to -25 deg.C in inert solvent. The protective groups are then split off selectively, acetyl groups by reacting with zinc acetate-sodium acetate in methanol-tetrahydrofuran and formyl groups with zinc acetate in methanol. The mixture is then subjected to hydrogenolysis in the presence of ca. 0.5% of Pd.-metal catalyst at 20-40 deg.C, pref. in alcohol with 10-50% acetone.

Description

  

  
 



  Verfahren zur Herstellung von geschützter   4,6-O-Alkyliden-P-D-glucopyranose   
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von   4,6-O-Alkyliden-ss-D-glucopyra-    nose der allgemeinen Formel I, worin R1 eine Alkylgruppe mit 1 bis 5 Kohlenstoffatomen bedeutet und R2 für die Formyl- oder Acetylgruppe steht.



   Erfindungsgemäss gelangt man zu den Verbindungen der allgemeinen Formel I, indem man eine 4,6-0 Alkylidenglucopyranose der allgemeinen Formel II, worin R1 obige Bedeutung hat, mit Natronlauge in das Natriumsalz überführt und dieses in einem wasserfreien, unter den Reaktionsbedingungen inerten Lösungsmittel mit Chlorameisensäurebenzylester zu Verbindungen der allgemeinen Formel III, worin R1 obige Bedeutung hat, umsetzt.

  Hierauf werden durch Umsetzung mit aktivierten Derivaten der Essigsäure beziehungsweise der Ameisensäure, beispielsweise mit Essigsäureanhydrid beziehungsweise mit Ameisensäureessigsäureanhydrid, in Gegenwart von Pyridin die Acetyl- beziehungsweise die Formylgruppen eingeführt, und die so erhaltenen Verbindungen der allgemeinen Formel IV, worin R1 und R2 obige Bedeutung besitzen, mit Wasserstoff in Gegenwart von Palladiummetall in trockenem Aceton behandelt, wobei die Verbindungen der allgemeinen Formel I erhalten werden.



   Für die hydrogenolytische Abspaltung der Benzyloxycarbonylgruppe kommt nur Palladiummetall in Frage, das durch Reduktion von Palladiumchlorid frisch hergestellt wird. Die Hydrogenolyse wird hierbei in einem trockenen hydroxylfreien Lösungsmittel, vorzugsweise Aceton, durchgeführt.



   Die 4,6-O-Alkylidenglucopyranose der allgemeinen Formel II wird durch säurekatalytische Behandlung eines aliphatischen Aldehyds mit Glucose hergestellt.



   Die Verbindungen der allgemeinen Formel I können beispielsweise als Ausgangsstoffe für die Herstellung von pharmazeutisch wertvollen 4'-Demethyl-epipodo   phyllotoxin-ss-D-alkylidenglucosiden    dienen.



   In den nachfolgenden Beispielen, welche die Ausführung des Verfahrens erläutern, den Umfang der Erfindung aber in keiner Weise einschränken sollen, erfolgen alle Temperaturangaben in Celsiusgraden. Die Schmelz- beziehungsweise Zersetzungspunkte sind auf dem Kofler-Block bestimmt.
EMI1.1     
  



   Beispiel 1   4,6-O-Äthyliden-2,3-di-O-acetyl-p-D-glucopyranose    a) Natriumsalz der   4,6-O-Athyliden-D-glucose   
Zu 102 ml auf   0     gekühlter 2n Natronlauge gibt man 41,6 g 4,6-O-Äthyliden-D-glucose und rührt bis zur Lösung. Danach setzt man ein Gemisch von 1000 ml   Äthanol-Äther    (3:2) zu, rührt 15 Minuten unter Eiskühlung, filtriert von der Fällung ab, wäscht mit 200 ml Äthanol, dann mit 300   ml    Äther und trocknet im Hochvakuum bei Zimmertemperatur, wobei das Natriumsalz der 4,6-O-Äthyliden-D-glucose erhalten wird.



  b) 4,6-O-Äthyliden-1-O-benzyloxycarbonyl-ss-D glucopyranose
Eine Suspension von 40 g Natriumsalz der 4,6-0 Äthyliden-D-glucose in 750 ml abs. und alkoholfreiem Chloroform versetzt man mit 40 g   75 einem    Chlorameisensäurebenzylester und rührt 16 Stunden unter Feuchtigkeitsausschluss bei 200. Danach wird mit 160 ml Ispopropanol versetzt, 5 Minuten gerührt, 200 ml Chloroform-Isopropanol (4: 1) zugegeben und dreimal mit je 100 ml Wasser gewaschen. Die organische Phase wird nach Trocknung über Natriumsulfat im Vakuum eingedampft, und der Rückstand dreimal mit je 150 ml Äther ausgezogen. Den   ither-un-    löslichen Rückstand löst man in 900   ml    heissem Äthylacetat, konzentriert im schwachen Vakuum auf 300 ml und lässt kristallisieren.

  Man erhält 4,6-0   Äthyliden-1-O-b enzyloxycarbonyl-ss-D-glucose,    die nach erneuter Kristallisation aus Äthylacetat bei   168-1690      schmilzt (Nadeln); [aW1 = -27,70 (c = 1,044 in Chloro-    form).



  c)   4,6-O-Äthyliden-1-O-benzyloxycarbonyl-2,3-di-O-       acel-ss-D-giucopyranose   
Zu einem Gemisch von 50 ml abs. Pyridin und 50 ml Essigsäureanhydrid gibt man 42,5 g 4,6-0   Äthyliden-1-O-benzyloxycarbonyl    - ss - D- glucopyranose und lässt 15 Stunden unter anfänglicher Kühlung mit kaltem Wasser und dann bei 200 reagieren. Danach wird im Vakuum eingedampft, der Rückstand dreimal im Vakuum mit je 100 ml Benzol hochgezogen und aus 100 ml Aceton unter Zusatz von 30 ml Äther kristallisiert. Erneute Kristallisation aus Aceton-Äther-Pentan ergibt analysenreine   4,6-O-Äthyliden-l-O-benzyloxy-    carbonyl-2,3-di-O-acetyl-ss-D-glucopyranose vom Smp.



     1610;    [a]   D    = -46,10 (c = 0,954 in Chloroform).



  d)   4,6-O-Äthyliden-2,3-di-O-acetyl-ss-D-glucopyranose   
500 mg   PdCl2    werden in 50 ml Wasser gelöst und nach Zusatz von 100 ml Methanol 1 Stunde bei 200 und Atmosphärendruck hydriert. Danach dekantiert man die überstehende Lösung vom ausgefallenen Palladium-Metall ab, wäscht das Palladium dreimal mit je 100 ml Methanol sorgfältig von Säure frei und entfernt dann durch dreimaliges Waschen mit je 150 ml trokkenem Aceton das Methanol. Der so erhaltene Pd-Katalysator wird in 250 ml trockenem Aceton suspendiert, 25,5 g 4,6-O-Äthyliden-1-O-benzyloxycarbonyl   2,3-di-O-acetyl-B-D-glucopyranose    zugesetzt und 1 Stunde bei 200 und Atmosphärendruck hydriert.

  Nach Abfiltrieren des Katalysators wird dieser mit 100 ml trockenem Aceton gewaschen, das Filtrat im Vakuum bei 350 Badtemperatur eingedampft und der Rückstand 1 Stunde bei 300 im Hochvakuum getrocknet.



  Zur Kristallisation wird mit 50 ml Diisopropyläther von 30-350 übergossen und kristallisieren gelassen. Aus Aceton-Pentan fällt reine   4, 6-O-Äthyliden-2, 3 -di-O-    acetyl-ss-D-glucopyranose vom Smp.   109-1110    an; [a]   D    =   -35,90    (c = 1,006 in Chloroform).



   Beispiel 2    4,6-O-Athyliden-2,3 -di-O-formyl-ss-D-glucopyranose    a)   4,6-O-Äthyliden-1-O-benzyloxycarbonyl-2,3-di-O-       formyl-ss-D-glucopyranose   
25,5 g   4,6-O-Äthyliden-1-O-benzyloxycarbonyl-fl-D-    glucopyranose werden in 200 ml abs. Methylenchlorid suspendiert. Die Suspension wird auf   -200    gekühlt und nach Zugabe von 86 ml   Ameisensäure-essigsäureanhydrid    (Herstellung siehe unten) 10 Minuten bei   -200    gerührt.



  Anschliessend lässt man unter Rühren und Feuchtigkeitsausschluss bei   -200    Innentemperatur eine Lösung von 60   ml    abs. Pyridin in 100 ml abs. Methylenchlorid innert 45 Minuten zutropfen. 5 Minuten nach beendeter Zugabe des Pyridins wird mit 200 ml Methylenchlorid verdünnt, viermal mit je 250 ml Wasser gewaschen und die organische Phase nach Trocknung über Natriumsulfat im Vakuum eingedampft. Den ölig anfallenden Rückstand dampft man viermal mit je 100 ml Benzol im Vakuum ein und trocknet danach im Vakuum bei 600. Kristallisation aus 70 ml Aceton, unter Zusatz von 30 ml Pentan, ergibt ein schwach gefärbtes Kristallisat, das in 100 ml Aceton gelöst und mit 1 g Aktivkohle behandelt wird. Nach Abfiltration der Kohle wird im Vakuum auf etwa 60 ml eingeengt und nach Versetzen mit 50 ml trockenem Äther kristallisieren gelassen.

  Analysenreine   4,6-O-Athyliden-1-O-benzyloxycarbonyl-2,3-di-O- forrnyl-ss-D-glucopyranose    schmilzt bei   125-1260;    [a]   2D1    =   -38,20    (c = 1,022 in Chloroform).



     Ameisensäure-essigsäureanhydrid   
Zu 48   ml    Essigsäureanhydrid werden unter Rühren, Feuchtigkeitsausschluss und Eiskühlung innert 20-30 Minuten 38 ml wasserfreie Ameisensäure so zugetropft, dass die Innentemperatur 250 nicht übersteigt. Danach lässt man 4 Stunden bei 200 stehen. Das so erhaltene Anhydrid wird für die Formylierung verwendet.

 

  b) 4,6-O-Äthyliden-2,3 -di-O-formyl-ss-D-glucopyranose
Analog Beispiel 1, Stufe d), erhält man aus 24,0 g   4,6-O-Äthyliden-1-O-benzyloxycarbonyl-2,3 -di-O-    formyl-ss-D-glucopyranose mit der gleichen Menge Palladiumkatalysator nach der Hydrierung rohe   4,6-O-Äthylen-2,3 -di-O-formyl-ss-D-    glucopyranose, die nach Kristallisation aus trockenem   Aceton-Äther-Pentan    und dann zweimal aus trockenem Aceton-Äther analysenreine Kristalle vom Doppel-Smp.



     109-114 /135-137     liefert; [a]   D21    =   -37,90    (c = 1,052 in Chloroform). 



  
 



  Process for the preparation of protected 4,6-O-alkylidene-P-D-glucopyranose
The present invention relates to a process for the preparation of 4,6-O-alkylidene-ss-D-glucopyra- nose of the general formula I, in which R1 is an alkyl group with 1 to 5 carbon atoms and R2 is the formyl or acetyl group.



   According to the invention, the compounds of general formula I are obtained by converting a 4,6-0 alkylidene glucopyranose of general formula II, in which R1 has the above meaning, with sodium hydroxide solution into the sodium salt and this in an anhydrous solvent inert under the reaction conditions with benzyl chloroformate to compounds of the general formula III, in which R1 has the above meaning.

  The acetyl or formyl groups are then introduced by reaction with activated derivatives of acetic acid or formic acid, for example with acetic anhydride or with formic acid acetic anhydride, in the presence of pyridine, and the compounds of general formula IV thus obtained, in which R1 and R2 have the above meaning treated with hydrogen in the presence of palladium metal in dry acetone, the compounds of general formula I being obtained.



   For the hydrogenolytic cleavage of the benzyloxycarbonyl group, only palladium metal that is freshly prepared by reducing palladium chloride is suitable. The hydrogenolysis is carried out in a dry, hydroxyl-free solvent, preferably acetone.



   The 4,6-O-alkylidene glucopyranose of the general formula II is produced by the acid-catalytic treatment of an aliphatic aldehyde with glucose.



   The compounds of general formula I can serve, for example, as starting materials for the preparation of pharmaceutically valuable 4'-demethyl-epipodo phyllotoxin-ss-D-alkylidene glucosides.



   In the following examples, which illustrate the implementation of the process but are not intended to restrict the scope of the invention in any way, all temperatures are given in degrees Celsius. The melting or decomposition points are determined on the Kofler block.
EMI1.1
  



   Example 1 4,6-O-ethylidene-2,3-di-O-acetyl-p-D-glucopyranose a) Sodium salt of 4,6-O-ethylidene-D-glucose
41.6 g of 4,6-O-ethylidene-D-glucose are added to 102 ml of 2N sodium hydroxide solution cooled to 0 and the mixture is stirred until it dissolves. Then a mixture of 1000 ml of ethanol-ether (3: 2) is added, stirred for 15 minutes while cooling with ice, the precipitate is filtered off, washed with 200 ml of ethanol, then with 300 ml of ether and dried in a high vacuum at room temperature Sodium salt of 4,6-O-ethylidene-D-glucose is obtained.



  b) 4,6-O-ethylidene-1-O-benzyloxycarbonyl-ss-D glucopyranose
A suspension of 40 g of the sodium salt of 4,6-0 ethylidene-D-glucose in 750 ml of abs. and alcohol-free chloroform are mixed with 40 g of a benzyl chloroformate and stirred for 16 hours with exclusion of moisture at 200. Then 160 ml of isopropanol are added, the mixture is stirred for 5 minutes, 200 ml of chloroform-isopropanol (4: 1) are added and three times with 100 ml of water each time washed. After drying over sodium sulfate, the organic phase is evaporated in vacuo, and the residue is extracted three times with 150 ml of ether each time. The ither-insoluble residue is dissolved in 900 ml of hot ethyl acetate, concentrated in a weak vacuum to 300 ml and allowed to crystallize.

  4,6-0 ethylidene-1-O-b enzyloxycarbonyl-ss-D-glucose is obtained which, after recrystallization from ethyl acetate, melts at 168-1690 (needles); [aW1 = -27.70 (c = 1.044 in chloroform).



  c) 4,6-O-ethylidene-1-O-benzyloxycarbonyl-2,3-di-O-acel-ss-D-giucopyranose
To a mixture of 50 ml abs. Pyridine and 50 ml of acetic anhydride are added to 42.5 g of 4,6-0 ethylidene-1-O-benzyloxycarbonyl - ss - D-glucopyranose and allowed to react for 15 hours with cold water and then at 200 while initially cooling. It is then evaporated in vacuo, the residue is drawn up three times in vacuo with 100 ml of benzene each time and crystallized from 100 ml of acetone with the addition of 30 ml of ether. Recrystallization from acetone-ether-pentane gives analytically pure 4,6-O-ethylidene-1-O-benzyloxycarbonyl-2,3-di-O-acetyl-ss-D-glucopyranose of mp.



     1610; [a] D = -46.10 (c = 0.954 in chloroform).



  d) 4,6-O-ethylidene-2,3-di-O-acetyl-ss-D-glucopyranose
500 mg of PdCl2 are dissolved in 50 ml of water and, after adding 100 ml of methanol, hydrogenated for 1 hour at 200 and atmospheric pressure. The supernatant solution is then decanted from the precipitated palladium metal, the palladium is carefully washed free of acid three times with 100 ml of methanol each time and the methanol is then removed by washing three times with 150 ml of dry acetone each time. The Pd catalyst obtained in this way is suspended in 250 ml of dry acetone, 25.5 g of 4,6-O-ethylidene-1-O-benzyloxycarbonyl 2,3-di-O-acetyl-BD-glucopyranose are added and at 200 for 1 hour and atmospheric pressure hydrogenated.

  After the catalyst has been filtered off, it is washed with 100 ml of dry acetone, the filtrate is evaporated in vacuo at a bath temperature of 350 and the residue is dried for 1 hour at 300 in a high vacuum.



  For crystallization, 50 ml of diisopropyl ether of 30-350 is poured over it and allowed to crystallize. Pure 4,6-O-ethylidene-2,3-di-O-acetyl-ss-D-glucopyranose with a melting point of 109-1110 is obtained from acetone-pentane; [a] D = -35.90 (c = 1.006 in chloroform).



   Example 2 4,6-O-Ethylidene-2,3-di-O-formyl-ss-D-glucopyranose a) 4,6-O-Ethylidene-1-O-benzyloxycarbonyl-2,3-di-O-formyl -ss-D-glucopyranose
25.5 g of 4,6-O-ethylidene-1-O-benzyloxycarbonyl-fl-D-glucopyranose are dissolved in 200 ml of abs. Methylene chloride suspended. The suspension is cooled to -200 and, after the addition of 86 ml of formic acid-acetic anhydride (preparation see below), stirred for 10 minutes at -200.



  A solution of 60 ml abs is then left with stirring and with exclusion of moisture at an internal temperature of -200. Pyridine in 100 ml abs. Add methylene chloride dropwise within 45 minutes. 5 minutes after the end of the pyridine addition, the mixture is diluted with 200 ml of methylene chloride, washed four times with 250 ml of water each time and, after drying over sodium sulfate, evaporated in vacuo. The oily residue is evaporated four times with 100 ml of benzene each time in vacuo and then dried in vacuo at 600. Crystallization from 70 ml of acetone, with the addition of 30 ml of pentane, gives a pale colored crystals which are dissolved in 100 ml of acetone and with 1 g of activated carbon is treated. After filtering off the charcoal, the mixture is concentrated to about 60 ml in vacuo and, after adding 50 ml of dry ether, allowed to crystallize.

  Analytically pure 4,6-O-ethylidene-1-O-benzyloxycarbonyl-2,3-di-O-formyl-ss-D-glucopyranose melts at 125-1260; [a] 2D1 = -38.20 (c = 1.022 in chloroform).



     Formic Acetic Anhydride
38 ml of anhydrous formic acid are added dropwise to 48 ml of acetic anhydride with stirring, with exclusion of moisture and ice cooling, within 20-30 minutes so that the internal temperature does not exceed 250. It is then left to stand at 200 for 4 hours. The anhydride thus obtained is used for the formylation.

 

  b) 4,6-O-ethylidene-2,3-di-O-formyl-ss-D-glucopyranose
Analogously to Example 1, stage d), 24.0 g of 4,6-O-ethylidene-1-O-benzyloxycarbonyl-2,3-di-O-formyl-ss-D-glucopyranose with the same amount of palladium catalyst are obtained the hydrogenation crude 4,6-O-ethylene-2,3-di-O-formyl-ss-D-glucopyranose, which after crystallization from dry acetone-ether-pentane and then twice from dry acetone-ether, analytically pure crystals of the double M.p.



     109-114 / 135-137 provides; [a] D21 = -37.90 (c = 1.052 in chloroform).

 

Claims (1)

PATENTANSPRUCH PATENT CLAIM Verfahren zur Herstellung einer geschützten 4,6 0-Alkylidenfi-D-glucopyranose der allgemeinen Formel I, worin R1 eine Alkylgruppe mit 1 bis 5 Kohlenstoffatomen bedeutet und R2 für die Formyl- oder Acetylgruppe steht, dadurch gekennzeichnet, dass man eine 4,6-O-Alkylidenglucopyranose der allgemeinen Formel lI, worin R1 obige Bedeutung hat, mit Natronlauge in das Natriumsalz überführt, dieses mit Chlor ameisensäurebenzylester zu Verbindungen der allgemei nen Formel III, worin R1 obige Bedeutung hat, umsetzt, hierauf acetyliert beziehungsweise formyliert und aus den so erhaltenen Verbindungen der allgemeinen Formel IV, worin R1 und R2 obige Bedeutung haben, die Benzyloxycarbonylgruppe hydrogenolytisch mit Palladiummetall in einem trockenen hydroxylfreien Lösungsmittel abspaltet. Process for the preparation of a protected 4,6 0-alkylidenefi-D-glucopyranose of the general formula I, in which R1 is an alkyl group having 1 to 5 carbon atoms and R2 is the formyl or acetyl group, characterized in that a 4,6- O-alkylideneglucopyranose of the general formula II, in which R1 has the above meaning, is converted into the sodium salt with sodium hydroxide solution, this is converted with benzyl chloroate to compounds of the general formula III, in which R1 has the above meaning, then acetylated or formylated and from the resulting Compounds of the general formula IV, in which R1 and R2 have the above meanings, the benzyloxycarbonyl group is split off hydrogenolytically with palladium metal in a dry, hydroxyl-free solvent. UNTERANSPRUCH Verfahren nach Patentanspruch, dadurch gekennzeichnet, dass man als trockenes hydroxylfreies Lösungsmittel Aceton verwendet. SUBClaim Process according to patent claim, characterized in that acetone is used as the dry, hydroxyl-free solvent.
CH1489370A 1968-02-27 1970-10-08 Glucosides cytostatic activity CH518927A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CH1489370A CH518927A (en) 1968-02-27 1970-10-08 Glucosides cytostatic activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH284568A CH514578A (en) 1968-02-27 1968-02-27 Process for the production of glucosides
CH1489370A CH518927A (en) 1968-02-27 1970-10-08 Glucosides cytostatic activity

Publications (1)

Publication Number Publication Date
CH518927A true CH518927A (en) 1972-02-15

Family

ID=4242875

Family Applications (2)

Application Number Title Priority Date Filing Date
CH284568A CH514578A (en) 1968-02-27 1968-02-27 Process for the production of glucosides
CH1489370A CH518927A (en) 1968-02-27 1970-10-08 Glucosides cytostatic activity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CH284568A CH514578A (en) 1968-02-27 1968-02-27 Process for the production of glucosides

Country Status (9)

Country Link
AT (2) AT319971B (en)
BR (1) BR6906655D0 (en)
CA (1) CA956939A (en)
CH (2) CH514578A (en)
CS (2) CS153032B2 (en)
DK (2) DK123715B (en)
FI (1) FI48924C (en)
NL (1) NL166028C (en)
SU (2) SU447886A3 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3374317D1 (en) * 1982-11-26 1987-12-10 Nippon Kayaku Kk Process for producing 4'-demethyl-epipodophyllotoxin-beta-d-ethylidene-glucoside and acyl-derivative thereof
JPS61189230A (en) * 1985-02-19 1986-08-22 Nippon Kayaku Co Ltd Etoposide preparation
IL77334A (en) * 1985-12-16 1991-04-15 Univ Bar Ilan Synthesis of 9-epipodophyllotoxin glucoside derivatives and some novel intermediates therefor
US4904768A (en) * 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
US4935504A (en) * 1987-12-18 1990-06-19 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-acyl derivatives
US5036055A (en) * 1989-06-07 1991-07-30 Bristol-Myers Company Acylated derivatives of etoposide
US5066645A (en) * 1989-09-01 1991-11-19 Bristol-Myers Company Epipodophyllotoxin altroside derivatives
US5463040A (en) * 1994-06-28 1995-10-31 Teva Pharmaceutical Industries, Ltd. Method of preparing etoposide
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CL2009002207A1 (en) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compounds derived from 3-hydroxy-5- (9h-purin-9-yl) tetrahydrofuran-2-yl, an inhibitor of the replication of arn-dependent viral arn; pharmaceutical composition; use for the treatment of hepatitis c.
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
AP3515A (en) 2010-03-31 2016-01-11 Gilead Pharmasset Llc Nucleoside phosphoramidates
IL261721B (en) 2016-03-15 2022-07-01 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors

Also Published As

Publication number Publication date
CA956939A (en) 1974-10-29
SU406346A3 (en) 1973-11-05
AT303270B (en) 1972-11-27
AT319971B (en) 1975-01-27
DK123715B (en) 1972-07-24
NL6901619A (en) 1969-08-29
FI48924C (en) 1975-02-10
SU447886A3 (en) 1974-10-25
CS153032B2 (en) 1974-02-22
DK128563B (en) 1974-05-27
NL166028B (en) 1981-01-15
BR6906655D0 (en) 1973-01-09
FI48924B (en) 1974-10-31
NL166028C (en) 1981-06-15
CS153033B2 (en) 1974-02-22
CH514578A (en) 1971-10-31

Similar Documents

Publication Publication Date Title
DE2844292A1 (en) PYRROLOBENZODIAZEPINE, THE METHOD OF MANUFACTURING THEREOF AND THEIR USE FOR THE TREATMENT OF TUMOR DISEASES
CH518927A (en) Glucosides cytostatic activity
DE2458164C2 (en)
SU447886A1 (en) The method of obtaining protected 4,6-0-alkylidene - - -glucopyranose
IL25493A (en) Pregnano(17alpha,16alpha-d)oxazolines
DE2229223B2 (en) 2-nitro-5-imidazole derivatives and processes for their preparation
CH419113A (en) Process for the preparation of D-homo-androstane-18-acids
DE1695500B2 (en) PROCESS FOR PREPARING 1-METHYL-5-NITROIMIDAZOLE COMPOUNDS
AT200579B (en) Process for the preparation of the new 5-dibenzo [b, f] azepines
AT238888B (en) Process for the preparation of new 3α-hydroxy-11,20-dioxo-21-pregnanglyoxylic acids substituted in the 16-position by a methyl group
US3018286A (en) Methoxy-z-j
AT215089B (en) Process for the preparation of 6-hydroxy-3: 5-cyclopregnan-20-one
AT253704B (en) Process for the preparation of the new 7α-methyl-16α-hydroxy-estrone and its 3,16-diacetate
DE930565C (en) Process for the preparation of 1-phenyl-2-amino-1, 3-propanediols or of 1-phenyl-2-amino-1, 3-propanediols substituted in the phenyl radical
AT238380B (en) Process for the preparation of 9 (11), 16-pregnadienes
DE575470C (en) Process for the preparation of C, C-disubstituted derivatives of barbituric acid
DE2517770C3 (en) Process for the production of
AT278261B (en) Process for the preparation of 4- or 6-acylated Δ 4 -3-keto steroids
AT239967B (en) Process for the preparation of 18,20 oxidosteroids
DE1593213C3 (en) Process for the preparation of steroidazines excretion from 1248653
CH658059A5 (en) METHOD FOR PRODUCING 10-BROMINE VINCAMINES.
AT241707B (en) Process for the production of new estradiol derivatives
US3088954A (en) 16beta-hydroxymethyl androstanes
AT263229B (en) Process for the production of new 3-OR-11-Oxo-16-androstenes
DE1768275A1 (en) 3ss, 14ss-Dihydrovycarda-4,20 (22) -dienoltde and process for their preparation

Legal Events

Date Code Title Description
PL Patent ceased